Physician profile
Michael L Smitherman
NPI 1053303685
$39,162.89
in general payments reported to CMS, 2019-2025
39 companies · $3,850 in 2025
The $3,850 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,761 · 2020: $3,428 · 2021: $3,892 · 2022: $7,714 · 2023: $12K · 2024: $5,664 · 2025: $3,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,186 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,400 · Consulting Fee: $4,240 · Travel and Lodging: $1,463 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,185.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,400.00 |
| Consulting Fee | $4,240.00 |
| Travel and Lodging | $1,463.00 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,381.34 | 2019-2025 | Ofev, Cyltezo |
| Pfizer INC. | $3,665.28 | 2019-2022 | |
| Amgen INC. | $3,614.31 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Janssen Biotech, INC. | $3,178.10 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Abbvie INC. | $2,858.46 | 2019-2025 | |
| Horizon Therapeutics Plc | $2,236.50 | 2019-2023 | Krystexxa |
| Ucb, INC. | $2,150.42 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,034.74 | 2019-2025 | |
| Lilly USA, LLC | $761.09 | 2019-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $757.67 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $591.25 | 2020-2024 | Acthar |
| Radius Health, INC. | $500.71 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $492.49 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $468.57 | 2019-2024 | Orencia |
| Glaxosmithkline, LLC. | $467.06 | 2019-2025 | Benlysta, Nucala |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smitherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.